LBX Pharmacy Chain JSC (SHSE:603883) EBIT: ¥899 Mil (TTM As of Mar. 2026)


SHSE:603883 LBX Pharmacy Chain JSC SHSE:603883
69 GF Score
Price ¥11.26
GF Value ¥19.10
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is LBX Pharmacy Chain JSC EBIT?

LBX Pharmacy Chain JSC SHSE:603883 +2.46% 69 EBIT is ¥899 Mil as of Mar. 2026. GuruFocus rates SHSE:603883 with a GF Score™ of 69/100 and a GF Value™ of ¥19.10 (Significantly Undervalued). The stock has 4 warning signs investors should review.

LBX Pharmacy Chain JSC's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥414 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥899 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. LBX Pharmacy Chain JSC's annualized ROC % for the quarter that ended in Mar. 2026 was 9.92%. LBX Pharmacy Chain JSC's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 49.16%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. LBX Pharmacy Chain JSC's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 8.35%.


LBX Pharmacy Chain JSC  (SHSE:603883) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

LBX Pharmacy Chain JSC's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=1655.096 * ( 1 - 21.63% )/( (13188.89 + 12974.336)/ 2 )
=1297.0987352/13081.613
=9.92 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=19845.404 - 7990.072 - ( 2358.429 - max(0, 10164.211 - 8830.653+2358.429))
=13188.89

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=19907.237 - 7964.563 - ( 2668.574 - max(0, 10049.651 - 9017.989+2668.574))
=12974.336

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

LBX Pharmacy Chain JSC's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1655.096/( ( (3399.41 + max(-2046.308, 0)) + (3334.236 + max(-2089.974, 0)) )/ 2 )
=1655.096/( ( 3399.41 + 3334.236 )/ 2 )
=1655.096/3366.823
=49.16 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2107.725 + 3652.252 + 433.412) - (7990.072 + 0 + 249.625)
=-2046.308

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1988.46 + 3633.61 + 461.967) - (7964.563 + 0 + 209.448)
=-2089.974

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

LBX Pharmacy Chain JSC's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=899.226/10766.226
=8.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LBX Pharmacy Chain JSC EBIT Related Terms


LBX Pharmacy Chain JSC EBIT Historical Data

* Premium members only.

The historical data trend for LBX Pharmacy Chain JSC's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LBX Pharmacy Chain JSC EBIT Chart

LBX Pharmacy Chain JSC Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,154.12 1,439.75 1,593.44 1,094.22 886.44

LBX Pharmacy Chain JSC Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 400.99 275.45 202.17 7.84 413.77

LBX Pharmacy Chain JSC EBIT Competitor Comparison

For the Pharmaceutical Retailers subindustry, LBX Pharmacy Chain JSC's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LBX Pharmacy Chain JSC EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, LBX Pharmacy Chain JSC's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where LBX Pharmacy Chain JSC's EV-to-EBIT falls into.


SHSE:603883
69GF Score
LBX Pharmacy Chain JSC SHSE:603883
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LBX Pharmacy Chain JSC EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥899 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥899 Mil mean?
LBX Pharmacy Chain JSC (SHSE:603883) has a EBIT of ¥899 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on LBX Pharmacy Chain JSC.
Is LBX Pharmacy Chain JSC's EBIT too high?
LBX Pharmacy Chain JSC's current EBIT is ¥899 Mil. Overall, LBX Pharmacy Chain JSC has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LBX Pharmacy Chain JSC's EBIT compare to competitors?
LBX Pharmacy Chain JSC's EBIT of ¥899 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on LBX Pharmacy Chain JSC. LBX Pharmacy Chain JSC's current EBIT is ¥899 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LBX Pharmacy Chain JSC stock overvalued right now?
Based on GuruFocus' analysis, LBX Pharmacy Chain JSC (SHSE:603883) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥19.10, compared to a current price of ¥11.26 — trading 41% below its estimated fair value. The current EBIT is ¥899 Mil. LBX Pharmacy Chain JSC's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For LBX Pharmacy Chain JSC (SHSE:603883), the current EBIT is ¥899 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LBX Pharmacy Chain JSC (SHSE:603883) Overvalued in 2026?

Based on GuruFocus' analysis, LBX Pharmacy Chain JSC stock appears to be undervalued. The current stock price of ¥11.26 is trading 41% below its estimated GF Value™ of ¥19.10. GuruFocus considers LBX Pharmacy Chain JSC to be Significantly Undervalued.

Key valuation signals for SHSE:603883:

  • EBIT: ¥899 Mil
  • GF Value™: ¥19.10 vs. price of ¥11.26 (41% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603883 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


LBX Pharmacy Chain JSC Business Description

Address No. 288, Xiangya Road, Kaifu District, Hunan, Changsha, CHN, 410005
LBX Pharmacy Chain JSC is a China-based company engages in the sale of medicine and health products. The company is engaged in retailing drugs and other related products, including Chinese and Western medicine, prepared slices of Chinese crude drugs, health equipment, healthy food, and personal care products and life care products. The company is also involved in the wholesale and manufacture of drugs.
69GF Score

Get the complete analysis for SHSE:603883

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥11.26
Price
¥19.10
GF Value